Intermittent Androgen Blockade in Prostate Cancer: Rationale and Clinical Experience

2000 ◽  
Vol 38 (4) ◽  
pp. 365-371 ◽  
Author(s):  
J.M. Wolff ◽  
U.W. Tunn
Keyword(s):  
Prostate Cancer ◽  
Clinical Experience ◽  
Androgen Blockade

Alternative Nonsteroidal Antiandrogen Therapy for Advanced Prostate Cancer That Relapsed After Initial Maximum Androgen Blockade

2008 ◽  
Vol 180 (3) ◽  
pp. 921-927 ◽  
Author(s):  
Hiroyoshi Suzuki ◽  
Koji Okihara ◽  
Hideaki Miyake ◽  
Masato Fujisawa ◽  
Susumu Miyoshi ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Advanced Prostate Cancer ◽  
Antiandrogen Therapy ◽  
Androgen Blockade

Intermittent Androgen Suppression for Prostate Cancer: Rationale and Clinical Experience

1998 ◽  
Vol 34 (Suppl. 3) ◽  
pp. 37-41 ◽  
Author(s):  
M. Gleave ◽  
N. Bruchovsky ◽  
S.L. Goldenberg ◽  
P. Rennie
Keyword(s):  
Prostate Cancer ◽  
Clinical Experience ◽  
Intermittent Androgen Suppression ◽  
Androgen Suppression

scholarly journals Combined Androgen Blockade in Localized Prostate Cancer Treated With Definitive Radiation Therapy

2019 ◽  
Vol 17 (12) ◽  
pp. 1497-1504
Author(s):  
Lucas K. Vitzthum ◽  
Chris Straka ◽  
Reith R. Sarkar ◽  
Rana McKay ◽  
J. Michael Randall ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Radiation Therapy ◽  
High Risk ◽  
Cox Proportional Hazards ◽  
Hazard Ratio ◽  
Short Term ◽  
Combined Androgen Blockade ◽  
Significant Difference ◽  
Androgen Blockade

Background: The addition of androgen deprivation therapy to radiation therapy (RT) improves survival in patients with intermediate- and high-risk prostate cancer (PCa), but it is not known whether combined androgen blockade (CAB) with a gonadotropin-releasing hormone agonist (GnRH-A) and a nonsteroidal antiandrogen improves survival over GnRH-A monotherapy. Methods: This study evaluated patients with intermediate- and high-risk PCa diagnosed in 2001 through 2015 who underwent RT with either GnRH-A alone or CAB using the Veterans Affairs Informatics and Computing Infrastructure. Associations between CAB and prostate cancer–specific mortality (PCSM) and overall survival (OS) were determined using multivariable regression with Fine-Gray and multivariable Cox proportional hazards models, respectively. For a positive control, the effect of long-term versus short-term GnRH-A therapy was tested. Results: The cohort included 8,423 men (GnRH-A, 4,529; CAB, 3,894) with a median follow-up of 5.9 years. There were 1,861 deaths, including 349 resulting from PCa. The unadjusted cumulative incidences of PCSM at 10 years were 5.9% and 6.9% for those receiving GnRH-A and CAB, respectively (P=.16). Compared with GnRH-A alone, CAB was not associated with a significant difference in covariate-adjusted PCSM (subdistribution hazard ratio [SHR], 1.05; 95% CI, 0.85–1.30) or OS (hazard ratio, 1.02; 95% CI, 0.93–1.12). For high-risk patients, long-term versus short-term GnRH-A therapy was associated with improved PCSM (SHR, 0.74; 95% CI, 0.57–0.95) and OS (SHR, 0.82; 95% CI, 0.73–0.93). Conclusions: In men receiving definitive RT for intermediate- or high-risk PCa, CAB was not associated with improved PCSM or OS compared with GnRH alone.

scholarly journals PROGNOSTIC FACTORS FOR ESTROGEN THERAPY OF RELAPSED PROSTATE CANCER AFTER MAXIMAL ANDROGEN BLOCKADE (MAB)

2010 ◽  
Vol 101 (4) ◽  
pp. 597-602
Author(s):  
Seiji Nakata ◽  
Yoshiyuki Miyazawa ◽  
Yasushi Sasaki ◽  
Katsuya Nakano ◽  
Hirotomo Takahashi
Keyword(s):  
Prostate Cancer ◽  
Prognostic Factors ◽  
Estrogen Therapy ◽  
Maximal Androgen Blockade ◽  
Androgen Blockade
Sign in / Sign up

Export Citation Format

Share Document